Cyclin D1 and Cdk4 Mediate Development of Neurologically Destructive Oligodendroglioma
Open accessPublished version of a preprint
The DOI matches its Crossref record; 55 of the 58 references it cites were found in a registry or an index.
Abstract
Although the molecular changes that characterize gliomas have been studied, the pathogenesis of tumor development remains unclear. p21 contributes to gliomagenesis by stabilizing cyclin D1-cdk4 kinase complexes, suggesting that cyclin D1 and cdk4 may also be required for glial tumor development. In this study, we used a mouse model to attempt to confirm this hypothesis, finding that cyclin D1 and cdk4 played active roles in not only the tumor but also the tumor microenvironment. Loss of cdk4 blocked tumor development, but loss of cyclin D1 did not prevent gliomas from developing. Instead, loss of cyclin D1 impeded progression to higher stages of malignancy. Enforcing expression of cyclin D1 was insufficient to correct the progression defect observed in cyclin D1-deficient animals. In contrast, restoration of cdk4 in the cdk4-deficient animals restored cell proliferation and tumor formation, although at lower tumor grades. Notably, the failure of tumors in the cyclin D1- and cdk4-deficient animals to progress to higher grades was correlated with a failure to fully activate microglia in the tumor microenvironment. Moreover, when platelet-derived growth factor-transformed glial cells were engrafted orthotopically into the mice, the tumors that formed progressed to high grades in wild-type mice but not cyclin D1-deficient animals. Together, our findings establish that the cyclin D1-cdk4 axis is not only critical in glial tumor cells but also in stromal-derived cells in the surrounding tumor microenvironment that are vital to sustain tumor outgrowth.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“CDK4 is required for the proliferation of the tumor cells; however, reconstituting incipient CDK4 deficient tumor cells with CDK4 expression vectors is not sufficient for tumors to progress to a more aggressive state when the rest of the animal is CDK4 deficient.”
From CDK4/6 Inhibitors: The Mechanism of Action May Not Be as Simple as Once Thought (2018) · cites this paper as Ciznadija et al., 2011
The cited source says what the claim attributes to it.
In the citing paper
“In the oligodendroglioma model described above (Ciznadija et al., 2011), ectopic PDGF expression is sufficient to drive the initiation of disease in CDK4 positive tumor cells, but if the microenvironment is CDK4 deficient these low-grade lesions would not progress to high grade lethal malignancies.”
From CDK4/6 Inhibitors: The Mechanism of Action May Not Be as Simple as Once Thought (2018) · cites this paper as Ciznadija et al., 2011
In the citing paper
“The importance of CDK4 activity within the microenvironment was first demonstrated by crossing an RCAS-PDGF/nestin-TvA mouse model of oligodendroglioma into a CDK4 deficient background (Ciznadija et al., 2011). CDK4 is required for the proliferation of the tumor cells; however, reconstituting incipient CDK4 deficient tumor cells with CDK4 expression vectors is not sufficient for tumors to progress”
From CDK4/6 Inhibitors: The Mechanism of Action May Not Be as Simple as Once Thought (2018) · cites this paper as Ciznadija et al., 2011
In the citing paper
“The lack of progression in this model is associated with a defect in the maturation of tumor-associated microglia, which remain in a sentinel mode in the absence of CDK4.”
From CDK4/6 Inhibitors: The Mechanism of Action May Not Be as Simple as Once Thought (2018) · cites this paper as Ciznadija et al., 2011
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219
CDK inhibitors: positive and negative regulators of G1-phase progression
Sherr, C. J., & Roberts, J. M. (1999) · Genes & Development · doi:10.1101/gad.13.12.1501 · Cited by 6,115 · cited 2×
“its ability to phosphorylate the Rb tumor suppressor, which pushes cells through the G1-S phase boundary (13, 20, 23, 44).”
MANTOVANI, A., SOZZANI, S., LOCATI, M., ALLAVENA, P., & SICA, A. (2002) · Trends in Immunology · doi:10.1016/s1471-4906(02)02302-5 · Cited by 5,528 · cited 1×
“Such microglia are polarized toward a phenotype that is progrowth and immunosuppressive, leading to a state in which tumor cell growth and diffusion throughout the brain parenchyma becomes more likely (49).”
Cell cycle, CDKs and cancer: a changing paradigm
Malumbres, M., & Barbacid, M. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2602 · Cited by 3,957 · cited 1×
“The impact of the cyclin D1–cdk4 axis on tumor development and progression resides in its ability to phosphorylate the Rb tumor suppressor, which pushes cells through the G1-S phase boundary (13, 21, 24, 45).”
Microenvironmental regulation of metastasis
Joyce, J. A., & Pollard, J. W. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2618 · Cited by 3,684 · cited 2×
“This is especially true in glial tumors, in which development, progression, and, ultimately, invasion relies on extracellular cues derived from stromal cells, including astrocytes, neurons, and brain macrophages recruited into the growing tumor mass (30, 41).”
Microglia: Active sensor and versatile effector cells in the normal and pathologic brain
Hanisch, U.-K., & Kettenmann, H. (2007) · Nature Neuroscience · doi:10.1038/nn1997 · Cited by 3,676
Local self-renewal can sustain CNS microglia maintenance and function throughout adult life
Ajami, B., Bennett, J. L., Krieger, C., Tetzlaff, W., & Rossi, F. M. V. (2007) · Nature Neuroscience · doi:10.1038/nn2014 · Cited by 1,643 · cited 1×
“Because microglia are derived from resident cells of the central nervous system, and not hematopoietic cells infiltrating from the circulation (43, 44), we were unable to ask whether reconstituting cyclin D1–deficient animals with wild-type microglia was able to support tumor progression to higher states of malignancy…”
The WHO classification of tumors of the nervous system
Kleihues, P., Louis, D. N., Scheithauer, B. W., Rorke, L. B., Reifenberger, G., Burger, P. C., & Cavenee, W. K. (2002) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/61.3.215 · Cited by 1,547
Fry, D. W., Harvey, P. J., Keller, P. R., Elliott, W. L., Meade, M., Trachet, E., Albassam, M., Zheng, X., Leopold, W. R., Pryer, N. K., et al. (2004) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.1427.3.11 · Cited by 1,236
Malignant glioma: genetics and biology of a grave matter
Maher, E. A., Furnari, F. B., Bachoo, R. M., Rowitch, D. H., Louis, D. N., Cavenee, W. K., & DePinho, R. A. (2001) · Genes & Development · doi:10.1101/gad.891601 · Cited by 1,229 · cited 1×
“This constitutive growth factor signaling loop leads to excessive cellular proliferation, which is a fundamental property of malignant glial tumors (4), representing an unshackling of the checkpoints that control the cell cycle.”
Research works printed but not linked: 1
- Geng, 2001, Deletion of the p27Kip1 gene restores normal development in cyclin D1-deficient mice, 194
Cited by
Cell cycle proteins as promising targets in cancer therapy
Otto, T., & Sicinski, P. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2016.138 · Cited by 1,858
Targeting cell-cycle machinery in cancer
Suski, J. M., Braun, M., Strmiska, V., & Sicinski, P. (2021) · Cancer Cell · doi:10.1016/j.ccell.2021.03.010 · Cited by 564
Montalto, F. I., & De Amicis, F. (2020) · Cells · doi:10.3390/cells9122648 · Cited by 496
“Subsequent in vivo studies establish that the Cyclin D1/CDK4 axis plays a critical role not only in glial tumor cells but also in stromal-derived cells, which sustain tumor growth [95].”
BackgroundCDK4/6 Inhibitors: The Mechanism of Action May Not Be as Simple as Once Thought
Klein, M. E., Kovatcheva, M., Davis, L. E., Tap, W. D., & Koff, A. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.03.023 · Cited by 378
“The importance of CDK4 activity within the microenvironment was first demonstrated by crossing an RCAS-PDGF/nestin-TvA mouse model of oligodendroglioma into a CDK4 deficient background (Ciznadija et al., 2011).”
BackgroundSelf-citationCell cycle regulation and anticancer drug discovery
Jingwen, B., Yaochen, L., & Guojun, Z. (2017) · Cancer Biology & Medicine · doi:10.20892/j.issn.2095-3941.2017.0033 · Cited by 302
Metadata
- Authors
- Ciznadija, D., Liu, Y., Pyonteck, S. M., Holland, E. C., & Koff, A.
- Affiliations
- Memorial Sloan Kettering Cancer Center (US)
- Corresponding author
- Koff, Andrew
- Venue
- Cancer Research
- Published
- 2011-09-29
- Volume
- 71
- Issue
- 19
- Pages
- 6174-6183
- ISSN
- 0008-5472 (ISSN-L)
- 1538-7445
- PMC
- PMC3185142
- OpenAlex
- W2071335998
- Cited by
- 44
- References
- 58
- Citations by year
- 2026: 1 · 2025: 4 · 2024: 3 · 2023: 2 · 2022: 3 · 2021: 3 · 2020: 7 · 2018: 3 · 2017: 3 · 2016: 2 · 2015: 1 · 2014: 3 · 2013: 8 · 2012: 1
- FWCI
- 1.94
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Cancer Research (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- Golfers Against Cancer
- Memorial Sloan-Kettering Cancer Center
- National Cancer Institute (NCI-CA89563, R01CA089563, P30CA008748)
- Topics
- Health Sciences › Medicine › Oncology › Glioma Diagnosis and Treatment
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Life Sciences › Neuroscience › Developmental Neuroscience › Neurogenesis and neuroplasticity mechanisms
- Keywords
- cyclin D1, CDK4, oligodendroglioma, gliomagenesis, tumor microenvironment, microglial activation, tumor progression, p21, stromal cells, cell proliferation, mouse model
- MeSH terms
- Animals, Cell Transformation, Neoplastic, Chickens, Oligodendroglioma, Platelet-Derived Growth Factor, Mice, Knockout, Cyclin D1, Cell Proliferation, Cyclin-Dependent Kinase 4, Mice, Tumor Microenvironment
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Cyclin D1 and Cdk4 Mediate Development of Neurologically Destructive Oligodendroglioma. https://app.cochat.ai/papers/10.1158/0008-5472.can-11-1031
- The paper
- Ciznadija, D., Liu, Y., Pyonteck, S. M., Holland, E. C., & Koff, A. (2011). Cyclin D1 and Cdk4 Mediate Development of Neurologically Destructive Oligodendroglioma. Cancer Research. https://doi.org/10.1158/0008-5472.can-11-1031
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.